Clin2
NCT07461545Possibly a fitRecruiting

Apixaban for late portal vein clot after spleen surgery

CirrhosisSplenectomyPortal Vein ThrombosisHypertension, Portal

Treatments studied

Part of Digestive system clinical trials.

This trial tests if apixaban, a blood thinner, is more effective than aspirin at treating blood clots in the portal vein that form more than a year after laparoscopic spleen removal in people with cirrhosis and an enlarged spleen.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Diagnosed with cirrhosis (scarring of the liver) from any cause
  • Had an enlarged spleen with low blood counts due to the spleen
  • Had no portal vein clot before or within a year after your laparoscopic spleen removal at the study center
  • Developed a portal vein clot more than 12 months after that surgery
  • Not taking blood thinners or antiplatelet drugs (like oral contraceptives or aspirin) at study start

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07461532Recruiting
Apixaban for late portal vein clot after spleen surgery

This trial is testing whether a blood thinner called apixaban can treat a blood clot in the main vein to the liver (portal vein) that appeared more than a year after spleen surgery in people with cirrhosis. It compares apixaban to a low-dose aspirin to see if one works better with fewer side effects.

Yangzhou, Jiangsu
NCT07602062Not yet recruiting
New blood thinner for liver cirrhosis patients with variceal bleeding and portal vein clot

This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.

Shanghai
NCT07521332Recruiting· Phase 4
Testing Apixaban to Prevent Bleeding Complications in Cirrhosis

This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.

Hyderābād, Sindh
NCT06818279Not yet recruiting· Phase 2/Phase 3
Blood thinners for liver vein clot in cirrhosis

This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.

New Delhi, National Capital Territory of Delhi
NCT07132515Recruiting· Phase 4
Blood thinners for cirrhosis with portal vein clot

This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).

Al Mansurah, Dakahlia Governorate
NCT07755059Not yet recruiting
Blocking the splenic artery for hard-to-treat belly fluid in liver cirrhosis

This trial tests a procedure called splenic artery embolization (blocking part of the blood supply to the spleen) to reduce belly fluid buildup in people with advanced liver disease. It may help if your ascites has not improved with standard treatments and you are not a candidate for TIPS.

Boston, Massachusetts

Hear when a new Cirrhosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.